Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response

Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

(2021) Carlos Wert-Carvajal et al.   Scientific Reports

Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery

(2020) Qiutong Jin et al.   JOURNAL OF CONTROLLED RELEASE

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

(2020) Liangliang Wang et al.   Science Translational Medicine

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

(2019) Rajarsi Mandal et al.   SCIENCE

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

(2019) Rachael M. Zemek et al.   Science Translational Medicine

Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment

(2019) Juliane Günther et al.   Frontiers in Immunology

Lymphatic vessel remodeling and invasion in pancreatic cancer progression

(2019) Chia-Ning Shen et al.   EBioMedicine

PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo

(2019) Yu-Ting Yen et al.   Cells

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

(2018) Brian W. Labadie et al.   CLINICAL CANCER RESEARCH

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

(2017) Giovanni Germano et al.   NATURE

Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

(2017) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer

(2017) Andrea J. Savio et al.   Clinical Epigenetics

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

(2016) Vincent Chung et al.   CLINICAL CANCER RESEARCH

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

(2016) Bernhard Mlecnik et al.   IMMUNITY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms

(2016) Amy R Peck et al.   MODERN PATHOLOGY

PP2A's restraint of mTOR is critical for Treg cell activity

(2016) Greg M Delgoffe   NATURE IMMUNOLOGY

Phosphatase PP2A is requisite for the function of regulatory T cells

(2016) Sokratis A Apostolidis et al.   NATURE IMMUNOLOGY

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

(2015) Christopher S Hong et al.   CANCER BIOLOGY & THERAPY

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

(2015) L. Zhai et al.   CLINICAL CANCER RESEARCH

The consensus molecular subtypes of colorectal cancer

(2015) Justin Guinney et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

(2015) Tauno Metsalu et al.   NUCLEIC ACIDS RESEARCH

Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner

(2015) Jennifer B. Jackson et al.   NEOPLASIA

Synergistic Enhancement of Cancer Therapy Using a Combination of Ceramide and Docetaxel

(2014) Li-Xia Feng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors

(2014) Stefan M. Woerner et al.   MOLECULAR CARCINOGENESIS

The BRAF Oncoprotein Functions through the Transcriptional Repressor MAFG to Mediate the CpG Island Methylator Phenotype

(2014) Minggang Fang et al.   MOLECULAR CELL

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer

(2012) Y.-A. Tang et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Prostaglandin E2 promotes intestinal tumor growth via DNA methylation

(2012) Dianren Xia et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer

(2010) Jing Tan et al.   CANCER CELL

Nanomedicine

(2010) Betty Y.S. Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of mismatch repair and genomic stability by miR-155

(2010) N. Valeri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)

(2010) N. Valeri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Accurate and Sensitive Peptide Identification with Mascot Percolator

(2009) Markus Brosch et al.   JOURNAL OF PROTEOME RESEARCH

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

(2009) Toshiro Sato et al.   NATURE

An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1

(2008) Christin L. Hanigan et al.   GASTROENTEROLOGY